Health

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 piv...

2021-02-25 21:00 5169

Huami Corporation Announces Name Change to Zepp Health

BEIJING and CUPERTINO, Calif., Feb. 25, 2021 /PRNewswire/ -- Huami Corp . today announced it is changing its name internationally to Zepp Health Corp. (NYSE: ZEPP) and the ticker symbol of its American depositary shares listed on the NYSE to "ZEPP" to better reflec...

2021-02-25 20:56 9587

111 to Announce Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results on March 18, 2021

SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...

2021-02-25 19:00 4836

Zhuyeqing The Epitome of Chinese Green Tea Ranks High in the "2021 Global Top 10 Luxury Tea Brands"

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- On February 24, 2021, Chinese brand Zhuyeqingranked high in the "2021 Global Top 10 Luxury Tea Brands", a global list that is compiled exclusively by one of the top three brand valuation organizations, World Brand Lab, to rank the best international high-en...

2021-02-25 16:21 5362

Turnaround on track at Comvita

TAURANGA, New Zealand, Feb. 24, 2021 /PRNewswire/ -- Headlines * Reported NPAT $3.5M vs. ($13M) in PCP * Reported EBITDA* $10.6M vs. ($8.8M) in PCP, an improvement of $19.4M * Reported revenue $98.9M, +5.5% vs. PCP * Double-digit top and bottom-line growth in focus growth markets * Net ...

2021-02-25 07:38 7111

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients

SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...

2021-02-25 07:00 2782

I-Mab Announces Upcoming Participation at March Conferences

SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March....

2021-02-24 21:00 5050

Alternative meat startup Next Meats Co., Ltd and microalgae biotech company euglena Co., launch "NEXT Euglena Yakiniku EX" containing microalgae

TOKYO, Feb. 12, 2021 /PRNewswire/ -- Next Meats Co., LTD, the controlling shareholder of Next Meats Holdings, Inc. ("OTC: NXMH") announced that they had signed a joint product development agreement witheuglena Co., a biotech company also fromJapan which specializes in cultivating Euglena and Chlo...

2021-02-24 12:45 6143

WuXi Diagnostics Secures US$150 Million Series B Financing to Accelerate Market Penetration in Global Diagnostics Sector

SHANGHAI, Feb. 23, 2021 /PRNewswire/ -- WuXi Diagnostic Investment (Cayman) Limited ("WuXi Diagnostics") announced that it has completedUS$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. ("Thermo Fisher"), Shiyu Capital ("SHIYU"), ABC International...

2021-02-24 08:00 2800

Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.

TOKYO, Feb. 23, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS). HOS specializes in predictive analytics and clinical decision support that enable healthcare...

2021-02-24 07:00 9024

GBB Completes USD$3.8M Convertible Note Financing Led by Alibaba Hong Kong Entrepreneurs Fund

HONG KONG, Feb. 23, 2021 /PRNewswire/ -- Great Bay Bio Holdings Limited (hereinafter referred to as "GBB") today announced it has completed aUSD$3.8M Convertible Note Financing. Alibaba Hong Kong Entrepreneurs Fund (hereinafter referred to as "AEF") led the investment round with participation fro...

2021-02-23 23:00 2453

Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021

SUZHOU and SHANGHAI, China, Feb. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release ...

2021-02-23 21:00 8185

Surgical Wait Times Technology Now Available in Australia and New Zealand

Fastest Growing Canadian Health Technology Company Expands Into ANZ SYDNEY, Feb. 23, 2021 /PRNewswire/ -- Wait times in both Australia and New Zealand are too long and how patients are admitted for surgery hasn't changed in decades. Unlike elsewhere, the process is unnecessarily antiquated and ...

2021-02-23 05:00 1143

Curocell announces Korean FDA clearance of the IND for CRC01, a first in kind immune checkpoint receptors downregulated CD19 CAR-T therapy

DAEJEON, South Korea, Feb. 22, 2021 /PRNewswire/ -- Curocell, Inc., a clinical-stage biotech developing next-generation CAR-T (OVIS™) therapies, announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved its Phase 1/2 clinical study application forCRC01, CD19 CAR-T cell the...

2021-02-22 22:00 1668

ABclonal Biotechnology Completes $93 Million Series C Financing

WOBURN, Mass., Feb. 22, 2021 /PRNewswire/ -- ABclonal Biotechnology, a global life science tools and services provider, recently completed its$92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital. Other new and existing shareholders, such as Si...

2021-02-22 20:00 1907

Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial

* BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase2b PTSD trial * BNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected ADELAIDE, Australia, Feb. 22, 2021 /PRNewswire/ -- Bionomics Limited (ASX: B...

2021-02-22 19:00 3711

Completion of Patients' Recruitment for Proxalutamide's COVID-19 Hospitalised Study

SUZHOU, China, Feb.22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients inBrazil completed the recruitment of 588 patients. The data of the clinical trial is expected ...

2021-02-22 17:14 3460

China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split

TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...

2021-02-19 21:00 6148

Psychobiotic PS128 consumption shows benefits to Parkinson's symptoms in new clinical study

TAIPEI, Feb. 18, 2021 /PRNewswire/ -- Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson's disease (PD). The study was led by a neurologist, Dr.Chin-Song Lu, a renowned researcher for PD i...

2021-02-19 12:07 2083

GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology

NANJING, China, Feb. 18, 2021 /PRNewswire/ -- On February 7th, 2021, GenScript ProBio announced that it has successfully completed 3 X 200 L GMP production runs of recombinant human factor VIII (rhFVIII) for Beijing Neoletix Biological Technology Co., Ltd. (Neoletix). InMay 2019, GenScript ProBio...

2021-02-18 22:00 2222
1 ... 302303304305306307308 ... 313

Week's Top Stories